

### **Amendments to the Claims**

Please cancel claims 1, 2, 4-6 and 8-12 without prejudice or disclaimer. Please amend claims 3 and 7 as follows. Please add claims 13-22.

### **Listing of Claims**

This listing of claims will replace all prior versions and listings of claims in the application.

#### **1-2. (Canceled)**

**3. (Amended)** A chimeric CMV virus ~~comprising a genome having a plurality of polynucleotide sequences, linked in conventional phosphodiester linkage, wherein at least two of said polynucleotide sequences are derived from different clinical isolates or strains of CMV selected from the group consisting of Chimera I, Chimera II, Chimera III, Chimera IV and Towne/Toll1.~~

#### **4-6. (Canceled)**

**7. (Amended)** A The chimeric CMV virus of claim 3 which is Chimera I.

#### **8-12. (Canceled)**

**13. (New)** The chimeric CMV virus of claim 7 which comprises: (a) a polynucleotide sequence at least 90% identical to a high-passage Towne genome from nucleotides 1 to 3799; (b) a polynucleotide sequence at least 90% identical to a Toledo genome from nucleotides 15750 to 67568; (c) a polynucleotide sequence at least 90% identical to a high-passage Towne genome from nucleotides 81647 to 170499; (d) a polynucleotide sequence at least 90% identical to a Toledo genome from nucleotides 175069 to 203136; and (e) a polynucleotide sequence at least 90% identical to a Towne genome from nucleotides 205803 to S-term.

**14. (New)** The chimeric CMV virus of claim 7 which comprises: (a) a polynucleotide sequence at least 90% identical to a high-passage Towne genome from nucleotides 1 to 3799; (b) a crossover region from nucleotides 3800 to 15749; (c) a polynucleotide sequence at least 90% identical to a Toledo genome from nucleotides 15750 to 67568; (d) a crossover region from nucleotides 67569 to 81646; (e) a polynucleotide sequence at least 90% identical to a high-passage Towne genome from nucleotides 81647 to 170499; (f) a crossover region from nucleotides 170500 to 175068; (g) a polynucleotide sequence at least 90% identical to a Toledo

genome from nucleotides 175069 to 203136; and (e) a polynucleotide sequence at least 90% identical to a Towne genome from nucleotides 205803 to S-term.

15. **(New)** An immunogenic composition comprising the chimeric virus of claim 3.
16. **(New)** An immunogenic composition comprising the chimeric virus of claim 7.
17. **(New)** An immunogenic composition comprising the chimeric virus of claim 13.
18. **(New)** An immunogenic composition comprising the chimeric virus of claim 14.
19. **(New)** A method of prophylactic treatment of a human cytomegalovirus-related disease or condition comprising administering to a human an immunological composition of claim 15 in an amount sufficient to stimulate an immune response in said human.
20. **(New)** A method of prophylactic treatment of a human cytomegalovirus-related disease or condition comprising administering to a human an immunological composition of claim 16 in an amount sufficient to stimulate an immune response in said human.
21. **(New)** A method of prophylactic treatment of an human cytomegalovirus-related disease or condition comprising administering to a human the immunological composition of claim 17 in an amount sufficient to stimulate an immune response in said human.
22. **(New)** A method of prophylactic treatment of a human cytomegalovirus-related disease or condition comprising administering to a human an immunological composition of claim 18 in an amount sufficient to stimulate an immune response in said human.